



Aarey

DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS

GST No.: 27AAACA5253A1Z9
CIN No.: L99999MH1990PLC056538

HEAD OFFICE: 1227, HUBTOWN SOLARIS, N. S. PHADKE MARG, OPP. TELLJ GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA. ☎ : (022) 82872900/2999 E-mail : info@areydrugs.c
REGD. OFFICE & FACTORY: E-34, M.J.D.C, TARAPUR, BOISAR, DIST.: PALGHAR- 401 506. ☎ : (02525) 852165 E-mail : works@areydrugs.com Web : www.areydrugs

Date: 14th February, 2020

To,
Department of Corporate Services,
Bombay Stock Exchange,
1st Floor. P.J.Towers,
Dalal Street. Fort
Mumbai — 400001

Sub: UN-AUDITED QUARTERLY RESULT FOR THE QUARTER ENDED 31st
DECEMBER, 2019

Dear Sir/Ma'am,

Pursuant to listing agreement we are enclosing herewith the Un-audited financial results for the quarter ended 31st December, 2019 with limited review report of the auditors.

Kindly acknowledge the same & oblige.

Thanking You,

Yours faithfully,

For Aarey Drugs and Pharmaceuticals Limited

M.S. Shetkar

Managing Director
Ecl:a/a



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2019

Particulars	(Rs. In Lakhs)					
	3 months ended on 31.12.2019	3 months ended on 30.09.2019	3 months ended on 31.12.2018	9 months ended on 31.12.2019	9 months ended on 31.12.2018	Previous year ended on 31.03.2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from Operations	5,964.82	6,355.64	7,843.61	18,940.77	21,743.00	35,474.14
Other Income	84.57	91.73	73.21	327.20	251.80	433.83
TOTAL INCOME	6,049.39	6,447.37	7,916.82	19,267.97	21,994.80	35,907.97
EXPENSES						
Cost of Materials Consumed	5,582.25	6,107.86	7,536.43	18,040.72	20,872.17	34,097.28
Changes in Inventories	-	-	-	-	-	-
Excise Duty on Sale of Goods	-	-	-	-	-	-
General Administrative Expense	124.71	63.22	51.70	293.20	188.36	336.98
Selling and Distribution Exp	37.76	39.38	56.60	115.18	141.79	251.28
Depreciation and Amortization Expense	25.43	27.62	18.45	78.15	54.55	100.83
Finance Cost	50.49	45.98	98.21	138.75	157.30	222.99
Other Expenses	88.54	33.63	-	122.17	-	-
TOTAL EXPENSES	5,909.18	6,317.69	7,761.39	18,788.16	21,414.17	35,009.36
Profit Before Exceptional Items and Tax	140.21	129.68	155.43	479.80	580.63	898.61
Exceptional Items	-	-	-	-	-	-
Profit Before Tax	-	-	-	-	-	-
Tax Expenses:						
a) Current Tax	-	-	-	-	-	(225.01)
b) Deferred Tax	-	-	-	-	-	(19.42)
Profit for the year	140.21	129.68	155.43	479.80	580.63	654.18
Other Comprehensive Income						
Items that will not be reclassified subsequently to Profit or Loss	-	-	-	-	-	-
a) Items that will not be classified to profit and loss	-	-	-	-	-	-
b) Income tax relating to Items that will not be reclassified to Profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the year	140.21	129.68	155.43	479.80	580.63	654.18
Earnings Per Share						
a) Basic EPS (Rs.)	0.60	0.55	0.66	2.05	2.48	2.80
b) Diluted EPS (Rs.)	0.60	0.55	0.66	2.05	2.48	2.80
Number of Shares	2,33,84,684	2,33,84,684	2,33,84,684	2,33,84,684	2,33,84,684	2,33,84,684
Percentage of Shareholding	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

Notes :

- The above results are restated as per the applicable Indian Accounting Standard (Ind AS) and are approved by audit committee and taken on record by the Board of Directors at their meeting held on 14th February, 2019
- Status of Investor Complaints (Nos): Opening Balance as on 01.10.2019 - Nil ; Received During the Quarter - 0; Disposed Off During the Quarter - 0 ; Closing Balance as on 31.12.2019 - Nil.
- The Figures of the previous year/period have been regrouped wherever necessary.

Place: Tarapur
Date: 14th February, 2020


By Order of the Board of Directors
Mihir R. Ghatalia
Managing Director




LIMITED REVIEW REPORT

TO,
THE BOARD OF DIRECTORS,
AAREY DRUGS & PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of unaudited financial results of Aarey Drugs & Pharmaceuticals Limited for the quarter ended December 31st, 2019, being submitted by the Company in pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued there under and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review Conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DMKH & Co.
Chartered Accountants
FRN 116886W

Manish Kankani



Manish Kankani

Partner

M.No. 158020

UDIN: 20158020AAAABW8008

Mumbai

Date: 14th February, 2020

Reconciliation of Net Profit as per IND AS and IGAAP

(Rs. in Lakhs)

S.No.	Particulars	Quarter Ended		Year Ended
		31-Dec-19	30-Sept -2019	31-Mar-2019
1	Net Profit/(loss) after tax for the period as per IGAAP	140.21	129.68	673.60
2	Impact of IND AS on comprehensive Income	-	-	(19.42)
3	Impact of IND AS on other comprehensive Income	-	-	-
4	Total comprehensive income for the period as per IND AS	140.21	129.68	654.18

Place: Mumbai

Date: 14th February 2020



Certificate of Managing Director (MD)

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 31st December, 2019 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mihir R. Ghatalia
MD

Date: 14/02/2020

Place: Mumbai

Certificate of Chief Financial Officer (CFO)

I, Rajesh P. Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 31st December, 2019 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Rajesh P. Ghatalia

CFO

Date: 14/02/2020

Place: Mumbai